April 24, 2024

• 

[THE INVESTOR] Hugel’s earnings momentum will be regained, said SK Securities on March 27, maintaining a “buy” recommendation and raising the target price to 750,000 won (US$697.41) from 570,000 won.

It will begin to recover in the latter half as competition in the domestic filler market eases and exports will expand in earnest, said analyst Lee Dal-mi.

Its stock price has fallen 13 percent from the beginning of this year reflecting the slow earnings and delay in clinical trials in the US, and will be boosted by the completion of its toxin’s phase 3 clinical trials and gaining sales approval for its fillers in China, said the analyst. 

Compared to its peers, its stocks are also attractive in terms of valuation as its price-earnings ratio is 27 times this year and will be 22 times next year, she added.

By Hwang You-mee (glamazon@heraldcorp.com)